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Antenatal 
corticosteroids to 
reduce preterm deaths 
in low-income settings
The Comment1 by Kishwar Azad and 
Anthony Costello opposing scale-
up of antenatal corticosteroids 
misdirects the discussion of this 
topic towards speculation about 
differences in low-income settings. 
Our experience in Malawi provides 
a concrete example of the rapid 
scaling up of antenatal corticosteroid 
treatment with dexamethasone.
Malawi has the highest estimated 
preterm birth rate worldwide.2 In 
Bwaila Maternity Hospital, Lilongwe, 
that has more than 15 000 deliveries 
annually with more than 2900 preterm, 
we increased targeted coverage of 
antenatal corticosteroids from 8% to 
80% in 16 weeks in women at risk of 
preterm delivery from 24 to 34 weeks’ 
gestation. After this pilot study, we 
began programmes in three other 
hospitals, reaching 59–83% coverage 
from a baseline of 1–6% within 6 weeks. 
This intervention has thus far been 
associated with a drop in preterm 
neonatal mortality contribution 
from 60% to 24% at 0–6 days of age. 
Although this intervention was not 
done as part of a trial, and focuses only 
on quality improvement, we noted 
no increase in the rate of maternal or 
neonatal infections.
Antenatal corticosteroids induce fetal 
lung maturation through the same 
biological mechanism in low-income 
settings as in high-income settings 
and reduce the need for neonatal 
mechanical ventilation.3 Although 
antenatal corticosteroids might not be 
a so-called magic bullet as a standalone 
vertical intervention, no biological 
basis exists to presume that babies 
born preterm in resource-poor settings 
will succumb to respiratory distress 
syndrome any more than do those in 
resource-rich countries. I support the 
existing recommendation of a single-
course of antenatal corticosteroids to 
mothers at high risk of preterm birth 
between 24 weeks and 33 weeks’ 
gestation, but question Azad and 
Costello’s unrealistic prerequisite for 
round-the-clock access to level 2 care in 
a low-income setting.
Low-income settings, which have the 
highest burden of preterm neonatal 
deaths, urgently need proven beneﬁ cial 
interventions, not the assessment 
of therapeutic efficacy on the basis 
of resource proﬁ ling that could delay 
treatment. Contrary to Azad and 
Costello’s speculation,1 antenatal 
corticosteroids are likely to have a 
greater eﬀ ect in the absence of level 2 
care, not a lesser eﬀ ect.4 The diﬀ erence 
between low-income and high-income 
settings is not biology, but an increased 
burden of disease and reduced access to 
even basic health care. Our experience 
in Malawi oﬀ ers a powerful example for 
generalising this standard of care to the 
regions where it will save the most lives 
and also reduce neonatal disability.
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